Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance

ABBOTT LABORATORIES

2024-Q1 EPS reported $0.70 revenue$9,964,000,000

Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).
Organic base business sales grew 10.8% YoY; fifth consecutive double-digit quarter.
FY2024 adjusted EPS guidance raised to $4.55-$4.70 midpoint; organic sales growth 8.5%-10.0% ex-COVID tests.
Medical Devices organic sales +14.3%; FreeStyle Libre revenue $1.5B (+22.4% reported).
FDA approved TriClip for tricuspid regurgitation and i-STAT TBI test; quarterly dividend $0.55/share maintained.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABBOTT LABORATORIES reported the first quarter ended March 31, 2024 results: revenue $10.0 billion, EPS $0.70. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $10.0 billion
EPS: $0.70
Guidance: raised
Result: reported results

Exact text from the filing

Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year – Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth 1 ABBOTT PARK, Ill., April 17, 2024 — Abbott today announced financial results for the first quarter ended March 31, 2024. • First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.

View on SEC.gov

513 earnings releases filed in the last 30 days. Browse all earnings releases →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001628280-24-016497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.